al7bebe
عضو نشط
- التسجيل
- 24 مارس 2005
- المشاركات
- 10,052
شركة طبية نازل عليها خبر ومرتفع السهم 16 سنت 1.21
Chelsea Therapeutics to Present at the 14th Annual Rodman & Renshaw Global Healthcare Investment Conference
CHARLOTTE, N.C., Sept. 4, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 14th Annual Rodman & Renshaw Global Healthcare Investment Conference at 3:40 PM ET on Monday, September 10, 2012 at the Waldorf Astoria in New York City.
Joseph G. Oliveto, Chelsea's Interim Chief Executive Officer will provide a corporate update and an overview of the Northera™ (droxidopa) development program.
Mr. Oliveto's presentation will be webcast live and archived for 30 days on
About Chelsea Therapeutics
Chelsea Therapeutics (Nasdaq:CHTP) is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases, including central nervous system disorders. Chelsea is currently pursuing FDA approval in the U.S. for Northera™ (droxidopa), a novel, late-stage, orally-active therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension in patients with primary autonomic failure. For more information about the Company,
Chelsea Therapeutics to Present at the 14th Annual Rodman & Renshaw Global Healthcare Investment Conference
CHARLOTTE, N.C., Sept. 4, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 14th Annual Rodman & Renshaw Global Healthcare Investment Conference at 3:40 PM ET on Monday, September 10, 2012 at the Waldorf Astoria in New York City.
Joseph G. Oliveto, Chelsea's Interim Chief Executive Officer will provide a corporate update and an overview of the Northera™ (droxidopa) development program.
Mr. Oliveto's presentation will be webcast live and archived for 30 days on
About Chelsea Therapeutics
Chelsea Therapeutics (Nasdaq:CHTP) is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases, including central nervous system disorders. Chelsea is currently pursuing FDA approval in the U.S. for Northera™ (droxidopa), a novel, late-stage, orally-active therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension in patients with primary autonomic failure. For more information about the Company,